LAPIX Therapeutics Announces Completion of Enrollment in Rheumatoid Arthritis Arm of Ongoing LPX-TI641 Clinical Study
RA cohort fully enrolled with 44 subjects
LAPIX Therapeutics, a clinical-stage biotechnology company developing a novel immunomodulatory therapy for inflammatory and immune-mediated diseases, today announced the completion of enrollment in the rheumatoid arthritis (RA) arm of its ongoing clinical study evaluating LPX-TI641, the Company's lead therapeutic candidate and a first-in-class oral TIM 3/4 agonist.
The RA arm of the study has successfully enrolled all 44 planned subjects across two treatment cohorts. Twenty-four subjects are receiving LPX-TI641 at a dose of 300 mg over a three-month treatment period, while 20 subjects were enrolled in a 150 mg cohort receiving treatment for 28 days. All study participants will continue to undergo protocol-defined follow-up and safety assessments for 60 days following completion of treatment.
"Completion of enrollment in the rheumatoid arthritis arm represents an important milestone in the clinical development of LPX-TI641," said Anas Fathallah, CEO of LAPIX Therapeutics. "As a first-in-class TIM 3/4 agonist, LPX-TI641 was designed to restore immune homeostasis through a differentiated mechanism that has the potential to address a broad range of inflammatory diseases. We are encouraged by the progress of the study and look forward to advancing enrollment in the atopic dermatitis arm while continuing to generate clinical data that will inform the future development of the program."
